

Supplementary Table S1. Clinical characteristics of the study population

| Characteristics | NFG (n = 1,281) | IFG (n = 247) | T2DM (n = 370) | F/ χ^2 /H | P |
|---|-------------------------|-------------------------------------|------------------------------------|----------------|---------|
| Age | 52.45 ± 15.58 | 59.15 ± 12.57 [*] | 59.94 ± 12.06 [*] | 50.527 | < 0.001 |
| Gender, n (%) | | | | 6.173 | 0.046 |
| Male | 600 (46.84) | 103 (41.70) | 149 (40.27) | | |
| Female | 681 (53.16) | 144 (58.30) | 221 (57.03) | | |
| BMI (kg/m ²) | 24.76 ± 3.64 | 26.36 ± 3.72 [*] | 26.37 ± 3.61 [*] | 40.229 | < 0.001 |
| FBG (mmol/L) | 4.74 ± 0.44 | 6.07 ± 0.35 [*] | 9.20 ± 3.29 ^{*#} | 1266.529 | < 0.001 |
| INS ^a | 10.76 (7.99, 13.79) | 13.06 (9.96, 17.68) [*] | 13.19 (9.46, 19.04) [*] | 46.640 | < 0.001 |
| TC (mmol/L) | 4.45 ± 0.98 | 4.90 ± 0.98 [*] | 4.74 ± 1.09 [*] | 27.960 | < 0.001 |
| TG (mmol/L) ^a | 1.23 (0.82, 1.90) | 1.61 (1.10, 2.68) [*] | 1.79 (1.15, 2.77) [*] | 60.236 | < 0.001 |
| LDL-C (mmol/L) | 2.52 ± 0.77 | 2.84 ± 0.79 [*] | 2.55 ± 0.82 [#] | 16.359 | < 0.001 |
| HDL-C (mmol/L) | 1.25 ± 0.31 | 1.18 ± 0.31 [*] | 1.22 ± 0.29 | 5.649 | 0.004 |
| HOMA-IR ^a | 2.28 (1.66, 2.97) | 3.46 (2.75, 4.67) [*] | 5.09 (3.40, 8.04) ^{*#} | 399.426 | < 0.001 |
| HOMA-β ^a | 173.77 (123.20, 259.77) | 104.64 (79.28, 138.42) [*] | 54.91 (29.96, 93.24) ^{*#} | 512.632 | < 0.001 |
| 25(OH)D ₃ (ng/mL) ^b | 20.05 (15.43, 29.38) | 19.7 (15.70, 26.15) | 18.73 (14.98, 27.45) | 3.054 | 0.217 |
| 1,25(OH) ₂ D ₃ (ng/mL) ^b | 22.83 (15.80, 47.52) | 24.15 (19.01, 35.45) | 20.67 (12.90, 31.46) ^{*#} | 20.957 | < 0.001 |
| Hypertension, n (%) | | | | 68.183 | < 0.001 |
| No | 808 (63.27) | 118 (48.36) | 149 (40.60) | | |
| Yes | 469 (36.73) | 126 (51.64) | 218 (59.40) | | |
| Physical Activity, n (%) | | | | 20.565 | < 0.001 |
| Low | 472 (36.93) | 105 (42.86) | 176 (47.70) | | |
| Moderate | 254 (19.87) | 58 (23.67) | 69 (18.70) | | |
| High | 552 (43.19) | 82 (33.47) | 124 (33.60) | | |
| FAMTD, n (%) | | | | 19.972 | < 0.001 |
| No | 228 (74.51) | 214 (89.54) | 297 (81.59) | | |
| Yes | 78 (25.49) | 25 (10.46) | 67 (18.41) | | |

Note. Data were given as means ± SD for normally distributed variables (age, BMI, FBG, TC, LDL-C, HDL-C), median (P_{25} , P_{75}) for non-normally distributed variables [INS, TG, HOMA-IR, HOMA-β, 25(OH)D₃, 1,25(OH)₂D₃], n (%) for categorical variables, and the significance of differences between groups evaluated using ANOVA, Kruskal Wallis H or χ^2 tests, respectively. ^{*}: $P < 0.05$ compared with NFG; [#]: $P < 0.05$ compared with IFG; ^a: Normally distributed variables after log transform; ^b: Kruskal Wallis H test. NFG, normal fasting blood glucose; IFG, impaired fasting blood glucose; T2DM, type 2 diabetes mellitus; BMI, body mass index; FBG, fasting blood glucose; INS, fasting serum insulin; TC, total cholesterol; TG, triglyceride; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment of insulin resistance; HOMA-β, homeostasis model assessment of β-cell function; FAMTD, family history of T2DM.

Supplementary Table S2. Quantitative metabolic traits in non-T2DM subjects stratified according to genotype

| SNP genotype | rs2189480 | | | <i>P</i> | <i>P</i> ^a |
|---|------------------------|------------------------|------------------------|----------|-----------------------|
| | AA | CA | CC | | |
| <i>n</i> (%) | 804 (42.74) | 828 (44.02) | 249 (13.24) | | |
| BMI (kg/m ²) | 25.26 ± 3.74 | 25.37 ± 3.74 | 25.03 ± 3.55 | 0.518 | |
| FBG (mmol/L) | 5.83 ± 2.36 | 5.82 ± 2.30 | 5.61 ± 2.14 | 0.368 | 0.408 |
| INS (mIU/L) ^b | 11.38 (8.58, 15.70) | 11.19 (8.26, 14.78) | 11.74 (8.24, 15.53) | 0.954 | 0.837 |
| TC (mmol/L) | 4.59 ± 1.00 | 4.57 ± 1.04 | 4.47 ± 1.01 | 0.489 | 0.538 |
| TG (mmol/L) ^b | 1.44 (0.93, 2.16) | 1.34 (0.87, 2.09) | 1.29 (0.89, 2.09) | 0.144 | 0.129 |
| LDL-C (mmol/L) | 2.56 ± 0.78 | 2.50 ± 0.79 | 2.49 ± 0.71 | 0.413 | 0.397 |
| HDL-C (mmol/L) | 1.23 ± 0.29 | 1.24 ± 0.31 | 1.25 ± 0.33 | 0.704 | 0.653 |
| HOMA-IR ^b | 2.98 (1.98, 15.60) | 2.91 (1.96, 14.84) | 2.85 (1.83, 13.48) | 0.591 | 0.673 |
| HOMA-β ^b | 130.20 (29.49, 211.88) | 129.37 (34.66, 208.12) | 137.09 (70.93, 215.94) | 0.309 | 0.279 |
| 25(OH)D ₃ (ng/mL) ^c | 15.33 (6.36, 23.28) | 16.11 (6.44, 23.90) | 15.73 (8.35, 25.00) | 0.579 | |
| 1,25(OH) ₂ D ₃ (ng/mL) ^c | 29.45 (19.19, 87.27) | 33.78 (20.05, 89.62) | 31.14 (17.00, 92.48) | 0.298 | |

Note. Data were given as means ± SD for normally distributed variables (BMI, FBG, TC, LDL-C, HDL-C), median (P_{25} , P_{75}) for non-normally distributed variables [INS, TG, HOMA-IR, HOMA-β, 25(OH)D₃, 1,25(OH)₂D₃], *n* (%) for categorical variables. ^a: Adjusted for age, gender, BMI, drinking, smoking, physical activity, and family history of T2DM. *P* value for general liner model. ^b: Normally distributed variables after log transform; ^c: Kruskal Wallis H test. SNP, single nucleotide polymorphism; BMI, body mass index; FBG, fasting blood glucose; INS, fasting serum insulin; TC, total cholesterol; TG, triglyceride; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment of insulin resistance; HOMA-β, homeostasis model assessment of β-cell function.

Supplementary Table S3. Gene-environment interaction models using GMDR

| Model | Training Bal.Acc. | Testing Bal.Acc. | CVC | <i>P</i> |
|------------------------|-------------------|------------------|-------|----------|
| Rs2189480 BMI | 0.590 | 0.578 | 10/10 | 0.001 |
| Rs2189480 Hypertension | 0.597 | 0.598 | 10/10 | 0.001 |
| Rs2189480 TC | 0.554 | 0.553 | 10/10 | 0.001 |
| Rs2189480 TG | 0.598 | 0.599 | 10/10 | 0.001 |

Note. BMI, body mass index; TC, total cholesterol; TG, triglyceride; CVC, cross-validation consistency.